B-CELL NON-HODGKIN LYMPHOMA
Clinical trials for B-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new B-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for B-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a rheumatoid arthritis drug tame CAR-T's worst side effects?
Disease control CompletedThis phase 2 trial tested whether anakinra, a drug normally used for rheumatoid arthritis, can prevent two serious side effects of CAR-T cell therapy: cytokine release syndrome (CRS) and nerve damage. The study enrolled 27 adults with B-cell non-Hodgkin lymphoma who were receivin…
Matched conditions: B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 23, 2026 22:19 UTC
-
Promising combo therapy boosts survival in kids with aggressive blood cancers
Disease control CompletedThis study tested whether adding 6 doses of the targeted drug rituximab to standard chemotherapy helps children and teens with advanced B-cell non-Hodgkin lymphoma or B-cell leukemia live longer without the cancer coming back. The trial included 482 high-risk patients aged 6 mont…
Matched conditions: B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 22, 2026 12:06 UTC
-
New pill shows promise for hard-to-treat blood cancers in chinese patients
Disease control CompletedThis study tested an oral drug called LOXO-305 in 87 Chinese adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma whose cancer had returned or not responded to prior therapies. The main goal was to see how many patients had their tumors sh…
Matched conditions: B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 17, 2026 12:08 UTC
-
Engineered immune cells take aim at tough blood cancers
Disease control CompletedThis study tested whether a new type of immune cell therapy, called CD22 CAR T cells, could be made from patients' own blood cells and safely given to adults with hard-to-treat B-cell leukemia or lymphoma. The main goals were to see if the cells could be produced successfully and…
Matched conditions: B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Matthew Frank • Aim: Disease control
Last updated Jun 12, 2026 12:06 UTC